Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
Genomic rearrangement in anaplastic lymphoma kinase (ALK) gene occurs in 3−7% of patients with non-small-cell lung cancer (NSCLC). The detection of this alteration is crucial as ALK positive NSCLC patients benefit from ALK inhibitors, which improve both the patient's quality of life and overall...
Guardado en:
Autores principales: | Sánchez-Herrero Estela, Provencio Mariano, Romero Atocha |
---|---|
Formato: | article |
Lenguaje: | EN ES |
Publicado: |
De Gruyter
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5adcc9d796aa44beae1ace9bc24a82b4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Liquid biopsy. A challenge for clinical laboratories
por: Jiménez Wladimiro
Publicado: (2020) -
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Michela Verzè, et al.
Publicado: (2021) -
Utilidad clínica de la biopsia líquida para el diagnóstico y seguimiento de los pacientes con CPNM y EML4-ALK
por: Sánchez-Herrero Estela, et al.
Publicado: (2020) -
Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
por: Umberto Caterino, et al.
Publicado: (2021) -
Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)